Dukem Bio is strong, rising over 60% in early trading on the 20th, the first day it transferred from KONEX to the KOSDAQ market.
As of 9:36 a.m. on that day, Dukem Bio is trading at 12,920 won, up 4,920 won (61.50%) compared to the public offering price (8,000 won). During trading, it even surged to 14,100 won.
Dukem Bio, a corporation developing radioactive drugs, decided on a public offering price of 8,000 won, which is 35% lower than the lower end of the desired public offering price range (12,300 won to 14,100 won), after failing to attract interest in the demand forecast for institutional investors conducted from the 2nd to the 6th of this month. In the general investor subscription held from the 11th to the 12th, there was a competition ratio of 172 to 1. Subscription deposits amounting to 240 billion won were collected.
During a press briefing for its initial public offering (IPO) held on the 6th of this month, Dukem Bio presented long-term goals, stating it would initiate the development of therapeutic radioactive drug new drugs after becoming a global contract development manufacturing organization (CDMO) for radioactive drugs. Dukem Bio's sales last year amounted to 34.7 billion won, with an operating profit of 5.3 billion won, an increase of 7.1% and 238.7%, respectively, compared to the previous year.